IL122242A - צירוף של אנטיגן לקולטן אנגיוטנסין ii ואנטיגן לקולטן אפוקסי- סטרואידאל אלדוסטרון - Google Patents

צירוף של אנטיגן לקולטן אנגיוטנסין ii ואנטיגן לקולטן אפוקסי- סטרואידאל אלדוסטרון

Info

Publication number: IL122242A
Authority: IL; Israel
Prior art keywords: angiotensin; epoxy; receptor antagonist; compound; oxo
Prior art date: 1995-06-07

Application number

IL12224296A

Other languages

English (en)

Other versions

IL122242A0 (en

Original Assignee

Searle & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1996-06-05

Publication date

2001-07-24

1996-06-05 Application filed by Searle & Co filed Critical Searle & Co

1998-04-05 Publication of IL122242A0 publication Critical patent/IL122242A0/xx

2001-07-24 Publication of IL122242A publication Critical patent/IL122242A/he

Links

239000002333 angiotensin II receptor antagonist Substances 0.000 title claims abstract description 141
102000003979 Mineralocorticoid Receptors Human genes 0.000 title claims abstract description 35
108090000375 Mineralocorticoid Receptors Proteins 0.000 title claims abstract description 35
229940044551 receptor antagonist Drugs 0.000 title claims abstract description 32
239000002464 receptor antagonist Substances 0.000 title claims abstract description 32
229940126317 angiotensin II receptor antagonist Drugs 0.000 title claims abstract description 19
150000001875 compounds Chemical class 0.000 claims description 183
-1 3,5-dibutyl-1 H-1 ,2,4-triazol-l -yl Chemical group 0.000 claims description 53
150000003839 salts Chemical class 0.000 claims description 14
239000004593 Epoxy Substances 0.000 claims description 12
230000003637 steroidlike Effects 0.000 claims description 10
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
108010083387 Saralasin Proteins 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 3
150000004702 methyl esters Chemical class 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
PFGWGEPQIUAZME-NXSMLHPHSA-N saralasin Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)C1=CC=C(O)C=C1 PFGWGEPQIUAZME-NXSMLHPHSA-N 0.000 claims description 2
229960004785 saralasin Drugs 0.000 claims description 2
AGWFKXDTYITCSP-NHGLSFBUSA-N (8s,9s,10r,13r,14s,17r)-17-(2-carboxyethyl)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-7-carboxylic acid Chemical compound C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)CCC(O)=O)[C@@H]4[C@@H]3C(C(O)=O)CC2=C1 AGWFKXDTYITCSP-NHGLSFBUSA-N 0.000 claims 6
KLVDUSUYBDMJKR-SANMLTNESA-N (6s)-1-[(4-amino-3-methylphenyl)methyl]-5-(2,2-diphenylacetyl)-6,7-dihydro-4h-imidazo[4,5-c]pyridine-6-carboxylic acid Chemical compound C1=C(N)C(C)=CC(CN2C=3C[C@H](N(CC=3N=C2)C(=O)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C(O)=O)=C1 KLVDUSUYBDMJKR-SANMLTNESA-N 0.000 claims 1
108010064733 Angiotensins Proteins 0.000 claims 1
102000015427 Angiotensins Human genes 0.000 claims 1
239000002083 C09CA01 - Losartan Substances 0.000 claims 1
239000002080 C09CA02 - Eprosartan Substances 0.000 claims 1
239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
239000002081 C09CA05 - Tasosartan Substances 0.000 claims 1
239000002053 C09CA06 - Candesartan Substances 0.000 claims 1
YBZYNINTWCLDQA-UHKVWXOHSA-N acetic acid;(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(1h-imidazol-5-yl)prop Chemical compound O.CC(O)=O.C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)C1=CC=C(O)C=C1 YBZYNINTWCLDQA-UHKVWXOHSA-N 0.000 claims 1
229960000932 candesartan Drugs 0.000 claims 1
SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 1
229960004563 eprosartan Drugs 0.000 claims 1
OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 1
125000004494 ethyl ester group Chemical group 0.000 claims 1
229960002198 irbesartan Drugs 0.000 claims 1
YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
ZEUXAIYYDDCIRX-UHFFFAOYSA-N losartan carboxylic acid Chemical compound CCCCC1=NC(Cl)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)C=C1 ZEUXAIYYDDCIRX-UHFFFAOYSA-N 0.000 claims 1
229960000519 losartan potassium Drugs 0.000 claims 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
PZQSQRCNMZGWFT-QXMHVHEDSA-N propan-2-yl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC(C)C PZQSQRCNMZGWFT-QXMHVHEDSA-N 0.000 claims 1
229960001379 saralasin acetate Drugs 0.000 claims 1
229960000651 tasosartan Drugs 0.000 claims 1
ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 claims 1
229940123413 Angiotensin II antagonist Drugs 0.000 description 122
239000005557 antagonist Substances 0.000 description 42
229960002478 aldosterone Drugs 0.000 description 31
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 30
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 29
238000002648 combination therapy Methods 0.000 description 26
206010019280 Heart failures Diseases 0.000 description 21
229950006323 angiotensin ii Drugs 0.000 description 21
238000012360 testing method Methods 0.000 description 21
102000005862 Angiotensin II Human genes 0.000 description 20
101800000733 Angiotensin-2 Proteins 0.000 description 20
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 20
206010020772 Hypertension Diseases 0.000 description 19
230000002378 acidificating effect Effects 0.000 description 19
235000002639 sodium chloride Nutrition 0.000 description 18
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 18
125000000217 alkyl group Chemical group 0.000 description 17
238000003556 assay Methods 0.000 description 17
125000004432 carbon atom Chemical group C* 0.000 description 17
206010007559 Cardiac failure congestive Diseases 0.000 description 16
230000000694 effects Effects 0.000 description 15
229960002256 spironolactone Drugs 0.000 description 15
241000700159 Rattus Species 0.000 description 14
230000005764 inhibitory process Effects 0.000 description 14
125000003118 aryl group Chemical group 0.000 description 13
239000003795 chemical substances by application Substances 0.000 description 13
102000005962 receptors Human genes 0.000 description 13
108020003175 receptors Proteins 0.000 description 13
230000027455 binding Effects 0.000 description 12
239000002934 diuretic Substances 0.000 description 12
JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 12
229960001208 eplerenone Drugs 0.000 description 12
125000000623 heterocyclic group Chemical group 0.000 description 11
239000000203 mixture Substances 0.000 description 11
230000004044 response Effects 0.000 description 11
229910052717 sulfur Inorganic materials 0.000 description 10
229910052799 carbon Inorganic materials 0.000 description 9
230000001882 diuretic effect Effects 0.000 description 9
229910052757 nitrogen Inorganic materials 0.000 description 9
229910052760 oxygen Inorganic materials 0.000 description 9
239000001301 oxygen Substances 0.000 description 9
239000005541 ACE inhibitor Substances 0.000 description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
239000002253 acid Substances 0.000 description 8
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 8
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
230000037396 body weight Effects 0.000 description 8
239000011734 sodium Substances 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
125000003710 aryl alkyl group Chemical group 0.000 description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
125000000753 cycloalkyl group Chemical group 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000003814 drug Substances 0.000 description 7
238000009472 formulation Methods 0.000 description 7
125000001072 heteroaryl group Chemical group 0.000 description 7
125000005842 heteroatom Chemical group 0.000 description 7
125000001145 hydrido group Chemical group *[H] 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
230000036454 renin-angiotensin system Effects 0.000 description 7
125000004434 sulfur atom Chemical group 0.000 description 7
102000008873 Angiotensin II receptor Human genes 0.000 description 6
108050000824 Angiotensin II receptor Proteins 0.000 description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
239000002170 aldosterone antagonist Substances 0.000 description 6
229940083712 aldosterone antagonist Drugs 0.000 description 6
125000004183 alkoxy alkyl group Chemical group 0.000 description 6
125000003545 alkoxy group Chemical group 0.000 description 6
230000002860 competitive effect Effects 0.000 description 6
125000001316 cycloalkyl alkyl group Chemical group 0.000 description 6
125000001153 fluoro group Chemical group F* 0.000 description 6
125000005843 halogen group Chemical group 0.000 description 6
238000000034 method Methods 0.000 description 6
208000010125 myocardial infarction Diseases 0.000 description 6
125000004433 nitrogen atom Chemical group N* 0.000 description 6
229910052708 sodium Inorganic materials 0.000 description 6
239000000243 solution Substances 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
102100028255 Renin Human genes 0.000 description 5
108090000783 Renin Proteins 0.000 description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
125000003342 alkenyl group Chemical group 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
239000002775 capsule Substances 0.000 description 5
150000001721 carbon Chemical group 0.000 description 5
230000000747 cardiac effect Effects 0.000 description 5
125000001309 chloro group Chemical group Cl* 0.000 description 5
125000001188 haloalkyl group Chemical group 0.000 description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
125000002768 hydroxyalkyl group Chemical group 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
210000003734 kidney Anatomy 0.000 description 5
125000004430 oxygen atom Chemical group O* 0.000 description 5
230000028327 secretion Effects 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000011593 sulfur Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
208000024172 Cardiovascular disease Diseases 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
125000000304 alkynyl group Chemical group 0.000 description 4
125000004122 cyclic group Chemical group 0.000 description 4
201000010099 disease Diseases 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
230000001631 hypertensive effect Effects 0.000 description 4
230000006872 improvement Effects 0.000 description 4
150000007524 organic acids Chemical class 0.000 description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
125000006413 ring segment Chemical group 0.000 description 4
239000000126 substance Substances 0.000 description 4
125000001544 thienyl group Chemical group 0.000 description 4
230000002861 ventricular Effects 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
206010003445 Ascites Diseases 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
206010016654 Fibrosis Diseases 0.000 description 3
206010028594 Myocardial fibrosis Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
210000000709 aorta Anatomy 0.000 description 3
230000004872 arterial blood pressure Effects 0.000 description 3
239000002585 base Substances 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
125000001246 bromo group Chemical group Br* 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
230000007882 cirrhosis Effects 0.000 description 3
208000019425 cirrhosis of liver Diseases 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
238000011161 development Methods 0.000 description 3
230000035487 diastolic blood pressure Effects 0.000 description 3
125000004982 dihaloalkyl group Chemical group 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
125000002541 furyl group Chemical group 0.000 description 3
238000003304 gavage Methods 0.000 description 3
125000004441 haloalkylsulfonyl group Chemical group 0.000 description 3
125000004446 heteroarylalkyl group Chemical group 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
125000006684 polyhaloalkyl group Polymers 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000036584 pressor response Effects 0.000 description 3
125000004076 pyridyl group Chemical group 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
239000003826 tablet Substances 0.000 description 3
TYRGTHQUZVMKOF-UHFFFAOYSA-N 16,17-dihydro-15h-cyclopenta[a]phenanthrene Chemical group C1=CC=C2C3=CC=C4CCCC4=C3C=CC2=C1 TYRGTHQUZVMKOF-UHFFFAOYSA-N 0.000 description 2
244000025254 Cannabis sativa Species 0.000 description 2
206010007572 Cardiac hypertrophy Diseases 0.000 description 2
208000006029 Cardiomegaly Diseases 0.000 description 2
108010061435 Enalapril Proteins 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
206010041277 Sodium retention Diseases 0.000 description 2
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
108010004977 Vasopressins Proteins 0.000 description 2
102000002852 Vasopressins Human genes 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000004913 activation Effects 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
125000004448 alkyl carbonyl group Chemical group 0.000 description 2
125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
125000004414 alkyl thio group Chemical group 0.000 description 2
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 2
238000010171 animal model Methods 0.000 description 2
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
125000005135 aryl sulfinyl group Chemical group 0.000 description 2
125000004391 aryl sulfonyl group Chemical group 0.000 description 2
125000005110 aryl thio group Chemical group 0.000 description 2
125000004104 aryloxy group Chemical group 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
229960000830 captopril Drugs 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
125000004093 cyano group Chemical group *C#N 0.000 description 2
125000000392 cycloalkenyl group Chemical group 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000000378 dietary effect Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
229940030606 diuretics Drugs 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
229960000873 enalapril Drugs 0.000 description 2
230000029142 excretion Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000002825 functional assay Methods 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
244000144993 groups of animals Species 0.000 description 2
125000004440 haloalkylsulfinyl group Chemical group 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
238000010191 image analysis Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
125000000842 isoxazolyl group Chemical group 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
239000002395 mineralocorticoid Substances 0.000 description 2
125000006682 monohaloalkyl group Chemical group 0.000 description 2
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
125000002971 oxazolyl group Chemical group 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
125000000714 pyrimidinyl group Chemical group 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
210000002820 sympathetic nervous system Anatomy 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
150000003536 tetrazoles Chemical group 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
125000000335 thiazolyl group Chemical group 0.000 description 2
210000005239 tubule Anatomy 0.000 description 2
230000002792 vascular Effects 0.000 description 2
229960003726 vasopressin Drugs 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
CUCSSYAUKKIDJV-FAXBSAIASA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1h-indol-3-yl)propanoyl]-methylamino]-3-phenylpropanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-n-[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpent Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)N(C)C(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CUCSSYAUKKIDJV-FAXBSAIASA-N 0.000 description 1
125000006002 1,1-difluoroethyl group Chemical group 0.000 description 1
125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
PQRKWOSQTRDIPE-UHFFFAOYSA-N 2-[2-butyl-5-chloro-3-[(2-chlorophenyl)methyl]imidazol-4-yl]acetic acid Chemical compound CCCCC1=NC(Cl)=C(CC(O)=O)N1CC1=CC=CC=C1Cl PQRKWOSQTRDIPE-UHFFFAOYSA-N 0.000 description 1
YWCAWHQYKZOIJJ-UHFFFAOYSA-N 2-[2-butyl-5-chloro-3-[(2-nitrophenyl)methyl]imidazol-4-yl]acetic acid Chemical compound CCCCC1=NC(Cl)=C(CC(O)=O)N1CC1=CC=CC=C1[N+]([O-])=O YWCAWHQYKZOIJJ-UHFFFAOYSA-N 0.000 description 1
ASUUCGYEJLQCMW-UHFFFAOYSA-N 2-[4-[(3,5-dibutyl-1,2,4-triazol-4-yl)methyl]phenyl]benzoic acid Chemical compound CCCCC1=NN=C(CCCC)N1CC1=CC=C(C=2C(=CC=CC=2)C(O)=O)C=C1 ASUUCGYEJLQCMW-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
208000010470 Ageusia Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229940123073 Angiotensin antagonist Drugs 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
206010054936 Cardiac cirrhosis Diseases 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
208000016998 Conn syndrome Diseases 0.000 description 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
241001269524 Dura Species 0.000 description 1
208000007530 Essential hypertension Diseases 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
208000002682 Hyperkalemia Diseases 0.000 description 1
208000019025 Hypokalemia Diseases 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
229920005479 Lucite® Polymers 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
NZXKDOXHBHYTKP-UHFFFAOYSA-N Metohexital Chemical compound CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O NZXKDOXHBHYTKP-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
206010062991 Positive cardiac inotropic effect Diseases 0.000 description 1
NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000019666 ageusia Nutrition 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229940092229 aldactone Drugs 0.000 description 1
IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
125000004946 alkenylalkyl group Chemical group 0.000 description 1
125000004171 alkoxy aryl group Chemical group 0.000 description 1
125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
125000004691 alkyl thio carbonyl group Chemical group 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
239000002369 angiotensin antagonist Substances 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000001864 anti-aldosterone effect Effects 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
108010055530 arginyl-tryptophyl-N-methylphenylalanyl-tryptophyl-leucyl-methioninamide Proteins 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
125000004659 aryl alkyl thio group Chemical group 0.000 description 1
125000002785 azepinyl group Chemical group 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
208000013116 chronic cough Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
238000011262 co‐therapy Methods 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000008021 deposition Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
125000004983 dialkoxyalkyl group Chemical group 0.000 description 1
125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
125000003838 furazanyl group Chemical group 0.000 description 1
DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
108700032141 ganirelix Proteins 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000004994 halo alkoxy alkyl group Chemical group 0.000 description 1
125000004438 haloalkoxy group Chemical group 0.000 description 1
125000003106 haloaryl group Chemical group 0.000 description 1
230000005802 health problem Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
238000013299 hypertensive rat model Methods 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000007574 infarction Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
201000007170 intrinsic cardiomyopathy Diseases 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229960002683 methohexital Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000000885 nephron Anatomy 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
125000003585 oxepinyl group Chemical group 0.000 description 1
125000004043 oxo group Chemical group O=* 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
125000003884 phenylalkyl group Chemical group 0.000 description 1
125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
208000024896 potassium deficiency disease Diseases 0.000 description 1
229940070017 potassium supplement Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000009117 preventive therapy Methods 0.000 description 1
208000013846 primary aldosteronism Diseases 0.000 description 1
201000009395 primary hyperaldosteronism Diseases 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
201000001474 proteinuria Diseases 0.000 description 1
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000001422 pyrrolinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
206010037844 rash Diseases 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
239000003087 receptor blocking agent Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
210000002254 renal artery Anatomy 0.000 description 1
238000012552 review Methods 0.000 description 1
238000011808 rodent model Methods 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
231100000046 skin rash Toxicity 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
210000000106 sweat gland Anatomy 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000019270 symptomatic heart failure Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000003777 thiepinyl group Chemical group 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
210000004926 tubular epithelial cell Anatomy 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
230000001196 vasorelaxation Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229960002769 zofenopril Drugs 0.000 description 1
IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Quinoline Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyrrole Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

IL12224296A 1995-06-07 1996-06-05 צירוף של אנטיגן לקולטן אנגיוטנסין ii ואנטיגן לקולטן אפוקסי- סטרואידאל אלדוסטרון IL122242A (he)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US48645695A	1995-06-07	1995-06-07
PCT/US1996/009335 WO1996040257A1 (en)	1995-06-07	1996-06-05	Epoxy-steroidal aldosterone antagonist and angiotensin ii antagonist combination therapy for treatment of congestive heart failure

Publications (2)

Publication Number	Publication Date
IL122242A0 IL122242A0 (en)	1998-04-05
IL122242A true IL122242A (he)	2001-07-24

Family

ID=23931955

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12224296A IL122242A (he)	1995-06-07	1996-06-05	צירוף של אנטיגן לקולטן אנגיוטנסין ii ואנטיגן לקולטן אפוקסי- סטרואידאל אלדוסטרון

Country Status (21)

Country	Link
US (1)	US6653306B1 (he)
EP (1)	EP0831910B1 (he)
JP (1)	JPH11507627A (he)
KR (1)	KR100618466B1 (he)
CN (2)	CN1522701A (he)
AT (1)	ATE209047T1 (he)
AU (1)	AU725689B2 (he)
BR (1)	BR9609066A (he)
CA (1)	CA2224079A1 (he)
CZ (1)	CZ297975B6 (he)
DE (1)	DE69617235T2 (he)
DK (1)	DK0831910T3 (he)
ES (1)	ES2167571T3 (he)
IL (1)	IL122242A (he)
NO (1)	NO318184B1 (he)
NZ (1)	NZ310730A (he)
PL (1)	PL185150B1 (he)
PT (1)	PT831910E (he)
RO (1)	RO118046B1 (he)
RU (1)	RU2166330C2 (he)
WO (1)	WO1996040257A1 (he)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK92899A3 (en) *	1997-01-10	2000-08-14	Merck & Co Inc	Use of angiotensin ii antagonists to treat symptomatic heart failure
US6201002B1 (en)	1997-01-10	2001-03-13	Merck & Co., Inc.	Method for reducing mortality with an angiotensin II antagonist
US6306826B1 (en)	1997-06-04	2001-10-23	The Regents Of The University Of California	Treatment of heart failure with growth hormone
IL145237A0 (en) *	1999-03-05	2002-06-30	Searle & Co	Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease
US6211217B1 (en)	1999-03-16	2001-04-03	Novartis Ag	Method for reducing pericardial fibrosis and adhesion formation
US20030083342A1 (en) *	2002-08-27	2003-05-01	Steele Ronald Edward	Combination of organic compounds
WO2001087284A2 (en) *	2000-05-11	2001-11-22	Pharmacia Corporation	Aldosterone antagonist composition for release during aldosterone acrophase
NZ522953A (en) *	2000-06-22	2005-10-28	Novartis Ag	Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate
AU7804501A (en) *	2000-07-27	2002-02-13	Pharmacia Corp	Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
ATE338566T1 (de) *	2000-07-27	2006-09-15	Pharmacia Corp	Aldosteronantagonist und cyclooxygenase-2 hemmer- kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
US7482366B2 (en)	2001-12-21	2009-01-27	X-Ceptor Therapeutics, Inc.	Modulators of LXR
EP1465869B1 (en)	2001-12-21	2013-05-15	Exelixis Patent Company LLC	Modulators of lxr
US20050124624A1 (en) *	2002-03-15	2005-06-09	Gilbert Richard E.	4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for threating ang ii-mediated diseases
GB0212412D0 (en) *	2002-05-29	2002-07-10	Novartis Ag	Combination of organic compounds
CL2004000545A1 (es) *	2003-03-18	2005-01-28	Pharmacia Corp Sa Organizada B	Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
US20050153885A1 (en) *	2003-10-08	2005-07-14	Yun Anthony J.	Treatment of conditions through modulation of the autonomic nervous system
US20070123498A1 (en) *	2003-10-17	2007-05-31	Shetty Suraj S	Combination of organic compounds
DE602005025755D1 (de)	2004-06-04	2011-02-17	Teva Pharma	Irbesartan enthaltende pharmazeutische zusammensetzung
US8569277B2 (en)	2004-08-11	2013-10-29	Palo Alto Investors	Methods of treating a subject for a condition
EP1831225A2 (en)	2004-11-19	2007-09-12	The Regents of the University of California	Anti-inflammatory pyrazolopyrimidines
CN101024643A (zh) *	2006-02-20	2007-08-29	上海艾力斯医药科技有限公司	咪唑－5－羧酸类衍生物、制备方法及其应用
WO2007114926A2 (en)	2006-04-04	2007-10-11	The Regents Of The University Of California	Kinase antagonists
GB2467670B (en)	2007-10-04	2012-08-01	Intellikine Inc	Chemical entities and therapeutic uses thereof
MX2010007419A (es) *	2008-01-04	2010-11-12	Intellikine Inc	Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en)	2008-03-14	2015-03-31	Intellikine Llc	Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (en)	2008-03-14	2018-06-27	Intellikine, LLC	Kinase inhibitors and methods of use
BRPI0915231A2 (pt)	2008-07-08	2018-06-12	Intellikine Inc	compostos inibidores de quinase e métodos de uso
US20110224223A1 (en)	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
CA2738429C (en)	2008-09-26	2016-10-25	Intellikine, Inc.	Heterocyclic kinase inhibitors
EP2358720B1 (en)	2008-10-16	2016-03-02	The Regents of The University of California	Fused ring heteroaryl kinase inhibitors
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
CN102369205B (zh)	2009-01-30	2014-10-29	武田药品工业株式会社	稠环化合物和其用途
JP5789252B2 (ja)	2009-05-07	2015-10-07	インテリカイン，エルエルシー	複素環式化合物およびその使用
WO2011047384A2 (en)	2009-10-16	2011-04-21	The Regents Of The University Of California	Methods of inhibiting ire1
CA2799579A1 (en)	2010-05-21	2011-11-24	Intellikine, Inc.	Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja)	2010-11-10	2013-12-26	インフィニティーファーマシューティカルズ，インコーポレイテッド	複素環化合物及びその使用
ES2637113T3 (es)	2011-01-10	2017-10-10	Infinity Pharmaceuticals, Inc.	Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US9295673B2 (en)	2011-02-23	2016-03-29	Intellikine Llc	Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
AR088218A1 (es)	2011-07-19	2014-05-21	Infinity Pharmaceuticals Inc	Compuestos heterociclicos utiles como inhibidores de pi3k
HK1198443A1 (en)	2011-07-19	2015-04-24	无限药品股份有限公司	Heterocyclic compounds and uses thereof
MX2014002542A (es)	2011-08-29	2014-07-09	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y usos de los mismos.
CA2846496C (en)	2011-09-02	2020-07-14	The Regents Of The University Of California	Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US9199975B2 (en)	2011-09-30	2015-12-01	Asana Biosciences, Llc	Biaryl imidazole derivatives for regulating CYP17
US8809372B2 (en)	2011-09-30	2014-08-19	Asana Biosciences, Llc	Pyridine derivatives
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP2015532287A (ja)	2012-09-26	2015-11-09	ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア	Ｉｒｅ１の調節
AU2013337717B2 (en)	2012-11-01	2018-10-25	Infinity Pharmaceuticals, Inc.	Treatment of cancers using PI3 kinase isoform modulators
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
PT3052485T (pt)	2013-10-04	2021-10-22	Infinity Pharmaceuticals Inc	Compostos heterocíclicos e suas utilizações
MX382033B (es)	2014-03-19	2025-03-13	Infinity Pharmaceuticals Inc	Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2015160975A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2017048702A1 (en)	2015-09-14	2017-03-23	Infinity Pharmaceuticals, Inc.	Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en)	2016-03-17	2017-09-21	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
SG11201811237WA (en)	2016-06-24	2019-01-30	Infinity Pharmaceuticals Inc	Combination therapies
ES2984389T3 (es)	2016-06-29	2024-10-29	Univ Montreal	Heterociclos de biarilmetilo
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
EA202191152A1 (ru)	2018-10-29	2022-01-19	Миокардиа, Инк.	Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона
CA3121202A1 (en)	2018-11-30	2020-06-04	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
US11971205B2 (en)	2021-08-20	2024-04-30	Pioneer Family Brands, Inc.	Ice shaver with splash guard
US11982483B2 (en)	2021-08-20	2024-05-14	Pioneer Family Brands, Inc.	Ice shaver with multi-link control arm
US12044455B2 (en)	2021-08-20	2024-07-23	Pioneer Family Brands, Inc.	Ice shaver with thermally isolated shave deck

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI77669C (fi) *	1983-04-13	1989-04-10	Ciba Geigy Ag	20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US4880804A (en) *	1988-01-07	1989-11-14	E. I. Du Pont De Nemours And Company	Angiotensin II receptor blocking benzimidazoles
CA2053148A1 (en) *	1990-10-16	1992-04-17	Karnail Atwal	Dihydropyrimidine derivatives
US5049565A (en) *	1990-12-07	1991-09-17	Merck & Co., Inc.	Microbial transformation process for preparing anti-hypertensive products
CA2109524A1 (en) *	1991-05-10	1992-11-11	Prasun K. Chakravarty	Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
US6008210A (en) *	1992-04-21	1999-12-28	Weber; Karl T.	Use of aldosterone antagonists to inhibit myocardial fibrosis
US5529992A (en) *	1992-04-21	1996-06-25	Curators Of The University Of Missouri	Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
AU5449194A (en) *	1992-10-26	1994-05-24	Merck & Co., Inc.	Combinations of angiotensin-ii receptor antagonists and diuretics
CA2125251C (en) *	1993-06-07	2005-04-26	Yoshiyuki Inada	A pharmaceutical composition for angiotensin ii-mediated diseases

1996
- 1996-06-05 AU AU61577/96A patent/AU725689B2/en not_active Ceased
- 1996-06-05 RU RU98100250/14A patent/RU2166330C2/ru not_active IP Right Cessation
- 1996-06-05 CZ CZ0385097A patent/CZ297975B6/cs not_active IP Right Cessation
- 1996-06-05 AT AT96919170T patent/ATE209047T1/de not_active IP Right Cessation
- 1996-06-05 DK DK96919170T patent/DK0831910T3/da active
- 1996-06-05 BR BR9609066A patent/BR9609066A/pt not_active Application Discontinuation
- 1996-06-05 EP EP96919170A patent/EP0831910B1/en not_active Expired - Lifetime
- 1996-06-05 PT PT96919170T patent/PT831910E/pt unknown
- 1996-06-05 CN CNA2004100027960A patent/CN1522701A/zh active Pending
- 1996-06-05 DE DE69617235T patent/DE69617235T2/de not_active Expired - Fee Related
- 1996-06-05 NZ NZ310730A patent/NZ310730A/xx unknown
- 1996-06-05 CN CNB961961554A patent/CN1142793C/zh not_active Expired - Fee Related
- 1996-06-05 ES ES96919170T patent/ES2167571T3/es not_active Expired - Lifetime
- 1996-06-05 KR KR1019970709029A patent/KR100618466B1/ko not_active Expired - Fee Related
- 1996-06-05 PL PL96324001A patent/PL185150B1/pl not_active IP Right Cessation
- 1996-06-05 IL IL12224296A patent/IL122242A/he not_active IP Right Cessation
- 1996-06-05 RO RO97-02272A patent/RO118046B1/ro unknown
- 1996-06-05 WO PCT/US1996/009335 patent/WO1996040257A1/en not_active Ceased
- 1996-06-05 JP JP9501678A patent/JPH11507627A/ja not_active Ceased
- 1996-06-05 CA CA002224079A patent/CA2224079A1/en not_active Abandoned
1997
- 1997-01-09 US US08/781,786 patent/US6653306B1/en not_active Expired - Fee Related
2004
- 2004-11-23 NO NO19975741A patent/NO318184B1/no unknown

Also Published As

Publication number	Publication date
AU6157796A (en)	1996-12-30
ES2167571T3 (es)	2002-05-16
JPH11507627A (ja)	1999-07-06
CZ297975B6 (cs)	2007-05-09
ATE209047T1 (de)	2001-12-15
CN1142793C (zh)	2004-03-24
DK0831910T3 (da)	2002-05-21
EP0831910B1 (en)	2001-11-21
KR100618466B1 (ko)	2006-12-13
NO975741D0 (no)	1997-12-05
NO318184B1 (no)	2005-02-14
PL185150B1 (pl)	2003-03-31
WO1996040257A1 (en)	1996-12-19
EP0831910A1 (en)	1998-04-01
NO975741L (no)	1998-01-29
US6653306B1 (en)	2003-11-25
DE69617235T2 (de)	2002-07-25
AU725689B2 (en)	2000-10-19
BR9609066A (pt)	1999-01-26
CZ385097A3 (cs)	1998-06-17
NZ310730A (en)	2001-01-26
IL122242A0 (en)	1998-04-05
CA2224079A1 (en)	1996-12-19
RU2166330C2 (ru)	2001-05-10
RO118046B1 (ro)	2003-01-30
PL324001A1 (en)	1998-04-27
KR19990022548A (ko)	1999-03-25
DE69617235D1 (de)	2002-01-03
CN1192697A (zh)	1998-09-09
CN1522701A (zh)	2004-08-25
PT831910E (pt)	2002-05-31

Legal Events

Date	Code	Title
2002-02-10	FF	Patent granted
2002-02-10	KB	Patent renewed
2002-12-01	KB	Patent renewed
2006-08-01	KB	Patent renewed
2011-01-31	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
IL122242A (he)	2001-07-24	צירוף של אנטיגן לקולטן אנגיוטנסין ii ואנטיגן לקולטן אפוקסי- סטרואידאל אלדוסטרון
US6984633B2 (en)	2006-01-10	Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and epoxymexrenone
JP2916267B2 (ja)	1999-07-05	心筋線維症を抑制するための抗アルドステロン薬の使用
US20040102423A1 (en)	2004-05-27	Spironolactone and angiotensin II antagonist combination therapy for treatment of congestive heart failure
US20040067915A1 (en)	2004-04-08	Method to treat cardiofibrosis with a combination of an angiotensin II antagonist and spironolactone
US20040097476A1 (en)	2004-05-20	Use of low dose amount of aldosterone antagonist for treatment of cardiovascular disease
KR19980702099A (ko)	1998-07-15	심장혈관질환의 치료를 위한 안지오텐신 전환 효소 억제제와 부작용-감소된 양의 알도스테론 길항제의 조합 치료요법
US6093708A (en)	2000-07-25	Use of aldosterone antagonists to inhibit myocardial fibrosis
EP1469862A2 (en)	2004-10-27	Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions
AU2003202486B2 (en)	2005-06-16	Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for the treatment of congestive heart failure
AU2003214938A1 (en)	2003-09-02	Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions
EP0808171A2 (en)	1997-11-26	Combination of angiotensin converting enzyme inhibitor, side-effect-reduced amount of aldosterone antagonist and diuretic
AU4264200A (en)	2000-09-07	Spironolactone and angiotensin II antagonist combination therapy for treatment of congestive heart failure